The KaiNETIC global Phase 3 clinical program (NCT07284875) includes three global, double-blind, randomized, placebo-controlled Phase 3 trials to evaluate weekly doses of up to 10 mg of ribupatide (KAI-9531) administered by subcutaneous injection over 76 weeks:
- KaiNETIC-1: target enrollment of 1,800 adults with a BMI of 30 kg/m2 or greater, or a BMI of 27 kg/m2 or greater with a comorbidity, excluding type 2 diabetes.
- KaiNETIC-2: target enrollment of 1,700 adults with a BMI of 27 kg/m2 or greater with type 2 diabetes.
- KaiNETIC-3: target enrollment of 1,200 adults with a BMI of 35 kg/m2 or greater and without type 2 diabetes. This trial will include an arm that will be randomized to open-label semaglutide 2.4 mg subcutaneous weekly injection.